JP2009542595A5 - - Google Patents

Download PDF

Info

Publication number
JP2009542595A5
JP2009542595A5 JP2009517252A JP2009517252A JP2009542595A5 JP 2009542595 A5 JP2009542595 A5 JP 2009542595A5 JP 2009517252 A JP2009517252 A JP 2009517252A JP 2009517252 A JP2009517252 A JP 2009517252A JP 2009542595 A5 JP2009542595 A5 JP 2009542595A5
Authority
JP
Japan
Prior art keywords
methyl
compound
formula
independently hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009517252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542595A (ja
JP5283620B2 (ja
Filing date
Publication date
Priority claimed from GB0613473A external-priority patent/GB0613473D0/en
Priority claimed from GB0622825A external-priority patent/GB0622825D0/en
Priority claimed from GB0705263A external-priority patent/GB0705263D0/en
Priority claimed from GB0711439A external-priority patent/GB0711439D0/en
Application filed filed Critical
Priority claimed from PCT/EP2007/056675 external-priority patent/WO2008003697A1/en
Publication of JP2009542595A publication Critical patent/JP2009542595A/ja
Publication of JP2009542595A5 publication Critical patent/JP2009542595A5/ja
Application granted granted Critical
Publication of JP5283620B2 publication Critical patent/JP5283620B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009517252A 2006-07-06 2007-07-03 P2x7受容体アンタゴニストとしての置換n−フェニルメチル−5−オキソ−プロリン−2−アミドおよびそれらの使用方法 Expired - Fee Related JP5283620B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0613473.8 2006-07-06
GB0613473A GB0613473D0 (en) 2006-07-06 2006-07-06 Novel compounds
GB0622825.8 2006-11-15
GB0622825A GB0622825D0 (en) 2006-11-15 2006-11-15 Novel compounds
GB0705263A GB0705263D0 (en) 2007-03-19 2007-03-19 Novel compounds
GB0705263.2 2007-03-19
GB0711439.0 2007-06-13
GB0711439A GB0711439D0 (en) 2007-06-13 2007-06-13 Novel receptor antagonists and their methods of use
PCT/EP2007/056675 WO2008003697A1 (en) 2006-07-06 2007-07-03 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use

Publications (3)

Publication Number Publication Date
JP2009542595A JP2009542595A (ja) 2009-12-03
JP2009542595A5 true JP2009542595A5 (https=) 2010-08-19
JP5283620B2 JP5283620B2 (ja) 2013-09-04

Family

ID=38508907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517252A Expired - Fee Related JP5283620B2 (ja) 2006-07-06 2007-07-03 P2x7受容体アンタゴニストとしての置換n−フェニルメチル−5−オキソ−プロリン−2−アミドおよびそれらの使用方法

Country Status (25)

Country Link
US (2) US7718693B2 (https=)
EP (1) EP2049478B1 (https=)
JP (1) JP5283620B2 (https=)
KR (2) KR101398264B1 (https=)
AR (1) AR061815A1 (https=)
AU (1) AU2007271182B2 (https=)
BR (1) BRPI0714062A2 (https=)
CA (1) CA2655675A1 (https=)
CR (2) CR10545A (https=)
CY (1) CY1113415T1 (https=)
DK (1) DK2049478T3 (https=)
EA (1) EA016076B1 (https=)
ES (1) ES2385505T3 (https=)
HR (1) HRP20120505T1 (https=)
IL (1) IL196181A0 (https=)
MA (1) MA30607B1 (https=)
MX (1) MX2009000117A (https=)
NO (1) NO20090267L (https=)
PE (1) PE20080997A1 (https=)
PL (1) PL2049478T3 (https=)
PT (1) PT2049478E (https=)
SI (1) SI2049478T1 (https=)
TW (1) TW200819127A (https=)
UA (1) UA100227C2 (https=)
WO (1) WO2008003697A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CA2655675A1 (en) * 2006-07-06 2008-01-10 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
DE102006047619B4 (de) * 2006-10-09 2008-11-13 Clariant International Limited Verfahren zur Herstellung basischer Fettsäureamide
DE102006047617B4 (de) * 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
EP3329882B1 (en) * 2006-10-22 2023-09-20 IDEV Technologies, INC. Methods for securing strand ends and the resulting devices
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
WO2008116845A1 (en) * 2007-03-28 2008-10-02 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
JP2010522710A (ja) * 2007-03-29 2010-07-08 グラクソ グループ リミテッド P2x7調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
CA2682649A1 (en) 2007-04-03 2008-10-09 Glaxo Group Limited Imidazolidine carboxamide derivatives as p2x7 modulators
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
BRPI0822058A2 (pt) * 2007-12-18 2015-06-23 Glaxo Group Ltd Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
NZ586346A (en) 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
CN102046240B (zh) 2008-03-25 2014-06-25 阿费克蒂斯药品公司 新的p2x7r拮抗剂及其应用
DE102008017218B4 (de) * 2008-04-04 2011-09-22 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren
DE102008017216B4 (de) * 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
DE102008017214B4 (de) * 2008-04-04 2012-02-16 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden
DE102008017213B4 (de) * 2008-04-04 2012-08-09 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren
DE102008017217A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren
DE102008017219A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser
DE102008017215B4 (de) * 2008-04-04 2012-08-09 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
WO2010118921A1 (en) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
US8691556B2 (en) 2009-12-08 2014-04-08 Vanderbilt University Methods and compositions for vein harvest and autografting
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
EP2569281A1 (en) 2010-05-14 2013-03-20 Affectis Pharmaceuticals AG Novel methods for the preparation of p2x7r antagonists
DE102010056564A1 (de) 2010-12-30 2012-07-05 Clariant International Limited Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
EP2661433B1 (en) * 2011-01-04 2017-08-16 Novartis AG Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2681200A4 (en) * 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Akt 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (zh) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
EA024204B1 (ru) 2012-01-20 2016-08-31 Актелион Фармасьютиклз Лтд. Производные гетероциклических амидов в качестве антагонистов p2xрецептора
US9075975B2 (en) * 2012-02-21 2015-07-07 Andrew Bud Online pseudonym verification and identity validation
AR093921A1 (es) 2012-12-12 2015-06-24 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x7
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 P2x7 수용체 길항제로서의 인돌 카르복사미드 유도체
KR102222220B1 (ko) 2013-01-22 2021-03-03 이도르시아 파마슈티컬스 리미티드 P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
FR3026102A1 (fr) * 2014-09-19 2016-03-25 Univ Nice Sophia Antipolis Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
DE102016111711A1 (de) * 2016-06-27 2017-12-28 Abb Schweiz Ag Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme
US11077100B2 (en) * 2017-03-13 2021-08-03 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as P2X7 receptor antagonists
WO2019006074A1 (en) * 2017-06-28 2019-01-03 Indiana University Research And Technology Corporation PHARMACEUTICAL AGENT THAT RELATES TO THE P2X7 RECEIVER
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN112512520B (zh) 2018-03-29 2023-10-24 国家科学研究中心 治疗中的p2rx7调节剂
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
HUE073311T2 (hu) 2020-03-31 2026-01-28 Remicine Ip B V Hiperinflammatorikus szindróma kezelése

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651639A (en) * 1951-08-22 1953-09-08 American Cyanamid Co 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same
FR2273533A1 (fr) 1974-06-04 1976-01-02 Ferlux Sa Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5
JPH0699307B2 (ja) 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
US4772601A (en) 1988-01-25 1988-09-20 Hoechst-Roussel Pharmaceuticals, Inc. 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use
WO1997017958A1 (en) 1995-11-13 1997-05-22 Smithkline Beecham Corporation Hemoregulatory compounds
US6054579A (en) * 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
SE9704546D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO2000033788A2 (en) 1998-12-11 2000-06-15 American Biogenetic Sciences Inc. Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CN1215028C (zh) 2002-05-24 2005-08-17 中国科学院上海有机化学研究所 外消旋的联二酚的光学拆分方法
US7288538B2 (en) * 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
SI1663185T1 (sl) * 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
WO2007115403A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
CA2655675A1 (en) * 2006-07-06 2008-01-10 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
US7999119B2 (en) * 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
EA201300152A1 (ru) * 2006-11-27 2013-07-30 Х. Лундбекк А/С Гетероариламидные производные
JP2010520875A (ja) * 2007-03-09 2010-06-17 レノビス, インコーポレイテッド P2x7調節因子としてのビシクロヘテロアリール化合物およびその使用
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
WO2008116845A1 (en) * 2007-03-28 2008-10-02 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
JP2010522710A (ja) * 2007-03-29 2010-07-08 グラクソ グループ リミテッド P2x7調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
CA2682649A1 (en) * 2007-04-03 2008-10-09 Glaxo Group Limited Imidazolidine carboxamide derivatives as p2x7 modulators
BRPI0809567A2 (pt) * 2007-04-10 2014-09-23 Lundbeck & Co As H Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto

Similar Documents

Publication Publication Date Title
JP2009542595A5 (https=)
JP2010522711A5 (https=)
JP2010522709A5 (https=)
JP2010523623A5 (https=)
JP2010522710A5 (https=)
JP2019094345A5 (https=)
JP2013502431A5 (https=)
JP2014513110A5 (https=)
JP2020502047A5 (https=)
JP2009531376A5 (https=)
JP2020532547A5 (https=)
JP2011527331A5 (https=)
JP2018534286A5 (https=)
JP2016512531A5 (https=)
JP2019531279A5 (https=)
HRP20120505T1 (hr) Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe
JP2012532112A5 (https=)
JP2006528597A5 (https=)
JP2020507589A5 (https=)
JP2015500223A5 (https=)
JP2012507535A5 (https=)
JP2019525939A5 (https=)
JP2016500063A5 (https=)
JP2018509438A5 (https=)
JP2010516702A5 (https=)